Diabetes sugar level can be reduced too much, UK researchers warn

28 January 2010

Intense treatment to lower blood sugar in patients with diabetes could prove nearly as harmful as allowing glucose levels to remain high, a study says. British scientists have gauged the risk posed by hypoglycemia - a lack of sugar in the blood - in a major study of diabetics that also points to possible changes in treatment guidelines.

"Low and high mean HBa1c (an indicator of blood sugar) values were associated with increased all-cause mortality and cardiac events," writes Craig Currie, from Cardiff University, and colleagues, in a paper published in the prestigious journal The Lancet. "If confirmed, diabetes guidelines might need revision to include a minimum HBa1c value,' he added.

The Cardiff, Wales-based researchers looked at nearly 50,000 patients with type 2 diabetes and found the lowest glucose levels linked to a heightened risk of death. Significant differences in death rates between patients on insulin and those taking tablets are also flagged up.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical